{
    "clinical_study": {
        "@rank": "70353", 
        "acronym": "VERTICAL", 
        "arm_group": {
            "arm_group_label": "VRS-317", 
            "arm_group_type": "Experimental", 
            "description": "Active treatment arm"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1b/2a study of VRS-317 (long-acting growth hormone) in pediatric patients\n      with growth hormone deficiency. During Phase 1b, pediatric patients each will receive a\n      single subcutaneous injection of VRS-317. During the Phase 2a stage, patients will receive 6\n      months of VRS-317 treatment at dose levels selected from the Phase 1b stage. The primary\n      endpoints for the study are to determine the safety and efficacy of repeat dose VRS-317."
        }, 
        "brief_title": "Versartis Trial in Children to Assess Long-Acting Growth Hormone", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pediatric Growth Hormone Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Phase 1b, separate cohorts of patients will be tested in a single ascending dose format.\n      Safety review committee meetings will take place prior to escalating to each increasing dose\n      level. Enrolled patients will be monitored for 60 days for safety with PK/PD and safety labs\n      collected.\n\n      Two dose levels will be selected after completion of Phase 1b to be tested during Phase 2a\n      (6 months of continuous VRS-317 treatment). Safety and PK assessments will be made during\n      the Phase 2a stage. Patient heights will be measured by stadiometer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronological Age \u2265 3.0 years and \u2264 11.0\n\n          -  Diagnosis of GHD as documented by GH stimulation test\n\n          -  Below average height SDS at screening\n\n          -  Appropriate weight for Stature\n\n          -  Decreased IGF-I SDS at screening\n\n          -  Delayed bone age\n\n          -  Normal thyroid function test results at screening visit\n\n          -  Legally authorized representative informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any growth promoting agent\n\n          -  Documented history of, or current, significant disease\n\n          -  Chromosomal aneuploidy, significant gene mutations\n\n          -  Diagnosis of Attention Deficit Hyperactivity Disorder\n\n          -  Daily use of anti-inflammatory doses of glucocorticoid\n\n          -  Prior history of leukemia, lymphoma, sarcoma or cancer\n\n          -  Known allergy to constituents of the study drug formulation\n\n          -  Abnormal ocular findings at screening\n\n          -  Significant abnormality in screening laboratory studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718041", 
            "org_study_id": "VRS-317 Protocol 12VR2"
        }, 
        "intervention": {
            "arm_group_label": "VRS-317", 
            "description": "Active treatment arm", 
            "intervention_name": "Experimental: VRS-317", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Growth hormone", 
            "Growth hormone deficiency", 
            "Growth", 
            "Pediatric growth hormone deficiency", 
            "Long acting growth hormone", 
            "GHD", 
            "PGHD", 
            "VRS 317", 
            "Exten", 
            "Versartis"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clovis", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenwood Village", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallahassee", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Livingston", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Long-acting Human Growth Hormone (VRS-317) in Pre-pubertal Children With Growth Hormone Deficiency: A Randomized, Open-label, Multi-center, Phase 1b/2a Study of Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy After Subcutaneous Administration for 6 Months", 
        "other_outcome": [
            {
                "description": "Secondary efficacy measures during Phase 2a include change in height SDS and change in bone age after 6 months VRS-317 treatment.", 
                "measure": "Evaluate secondary efficacy measures after 6 months of VRS-317 dosing.", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Secondary outcome measures include evaluation of pharmacodynamics (PD) as measured by IGF-I and IGFBP-3 responses to single dose VRS-317 during Phase 1b and as measured by IGF-I and IGFBP-3 responses to multiple doses of VRS-317 after repeat dosing during Phase 2a. PD measures will be obtained at multiple timepoints during Phase 1b and Phase 2a.", 
                "measure": "Evaluate pharmacodynamic measures", 
                "safety_issue": "Yes", 
                "time_frame": "8 Months"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety observations will include the number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, single dose immunogenicity (Phase 1b), and repeat dose immunogenicity (Phase 2a).\nThe primary efficacy outcome measure is the height velocity over 6 months as measured by standing height taken with stadiometer at baseline and after 6 Months of VRS-317 dosing in Phase 2a.", 
            "measure": "Phase 1b and 2a: Evaluate the safety and tolerability of multiple dosing levels of subcutaneous (SC) VRS-317 in pediatric growth hormone deficient (GHD) patients. Phase 2a: Evaluate the efficacy of multiple dose levels of VRS-317", 
            "safety_issue": "Yes", 
            "time_frame": "8 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcome measures include evaluation of pharmacokinetics (PK) of VRS-317 including Cmax, Tmax and AUC. PK measures will be analysed at multiple timepoints after single dosing of VRS-317 during Phase 1b and after repeat dosing of VRS-317 during Phase 2a.", 
            "measure": "Evaluate pharmacokinetic measures of VRS-317.", 
            "safety_issue": "Yes", 
            "time_frame": "8 months"
        }, 
        "source": "Versartis Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Versartis Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}